Regeneron

News
ASH: Regeneron plays its PNH hand

ASH: Regeneron plays its PNH hand

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

Oncology
Israel Lowy from Regeneron interview with Nicole Raleigh

ESMO 2024 - Israel (Izzy) Lowy

ESMO 2024, which followed hot on the heels of this year’s World Conference on Lung Cancer, was abuzz with data around PD-1 inhibitors, LAG-3 inhibitors, and the possibilities for using exis

News
Dupixent

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f